Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma
Danijela Drakulic1, Marija Schwirtlich1, Isidora Petrovic1
1Laboratory for Human Molecular Genetics, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
Abstract:
Glioblastoma (GBM) is the most common and highly lethal type of brain tumor, with poor survival despite advances in understanding its complexity. After current standard therapeutic treatment, including tumor resection, radiotherapy and concomitant chemotherapy with temozolomide, the median overall survival of patients with this type of tumor is less than 15 months. Thus, there is an urgent need for new insights into GBM molecular characteristics and progress in targeted therapy in order to improve clinical outcomes. The literature data revealed that a number of different signaling pathways are dysregulated in GBM. In this review, we intended to summarize and discuss current literature data and therapeutic modalities focused on targeting dysregulated signaling pathways in GBM. A better understanding of opportunities for targeting signaling pathways that influences malignant behavior of GBM cells might open the way for the development of novel GBM-targeted therapies.
Insights
Glioblastoma (GBM) is a deadly brain cancer with poor survival rates. This review explores targeting dysregulated signaling pathways to develop novel GBM therapies and improve patient outcomes.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Glioblastoma (GBM) is the most prevalent and lethal primary brain tumor.
- Current treatments offer limited survival benefits, with median overall survival under 15 months.
- Significant unmet need exists for improved therapeutic strategies.
Purpose of the Study:
- To review and discuss current literature on targeting dysregulated signaling pathways in GBM.
- To highlight therapeutic modalities aimed at molecular targets within GBM.
- To identify opportunities for novel GBM-targeted therapies.
Main Methods:
- Comprehensive literature review of studies on GBM signaling pathways.
- Analysis of therapeutic approaches targeting molecular aberrations in GBM.
- Synthesis of data on the role of signaling pathways in GBM malignancy.
Main Results:
- Numerous signaling pathways are identified as dysregulated in GBM.
- Targeting these pathways shows potential for novel therapeutic interventions.
- Understanding pathway dysregulation is key to GBM cell behavior.
Conclusions:
- Targeting dysregulated signaling pathways represents a promising avenue for GBM treatment.
- Further research into molecular mechanisms can drive the development of effective therapies.
- Improved understanding may lead to better clinical outcomes for GBM patients.
More Related Videos
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019